Log In
BCIQ
Print this Print this
 

SEP-363856

  Manage Alerts
Collapse Summary General Information
Company Sumitomo Dainippon Pharma Co. Ltd.
DescriptionAntipsychotic
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today